MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix

International Journal of Gynecological Pathology

Volumn 33, Issue 5, 2014, Pages 517-523

  Kim, Younghye ^a   Choi, Jung Woo ^a   Lee, Ju Han ^a   Kim, Young Sik ^a  

^a Korea University   (South Korea)

Author keywords

CDC20; Cervical cancer; MAD2

Indexed keywords

CELL CYCLE PROTEIN 20; PROTEIN MAD2; CDC20 PROTEIN, HUMAN; MAD2L1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DYSPLASIA; FEMALE; GENE OVEREXPRESSION; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINIZATION; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SQUAMOUS EPITHELIUM; TISSUE MICROARRAY; TUMOR INVASION; UPREGULATION; UTERINE CERVIX; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CDC20 PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MAD2 PROTEINS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84906047014     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000082     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Bernard BA, Bailly C, Lenoir MC, et al. The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J Virol 1989;63:4317-24. (Pubitemid 19229429)
3. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009;384:324-34.
4. McLaughlin-Drubin ME, Munger K. The human papillomavirus E7 oncoprotein. Virology 2009;384:335-44.
5. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: Cutting through the mystery. Nat Rev Cancer 2001;1: 109-17. (Pubitemid 33741886)
6. Sudakin V, Chan GKT, Yen TJ. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 2001;154:925-36. (Pubitemid 34286173)
7. Lau DT, Murray AW. Mad2 and Mad3 cooperate to arrest budding yeast in mitosis. Curr Biol 2012;22:180-90.
8. Patel D, McCance DJ. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6 and E7-expressing keratinocytes. J Virol 2010;84:10956-64.
9. Schvartzman JM, Duijf PHG, Sotillo R, et al. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell 2011;19: 701-14.
10. Li GQ, Li H, Zhang HF. Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 2003;9:1972-5. (Pubitemid 37168424)
11. Mondal G, Sengupta S, Panda CK, et al. Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 2007;28: 81-92. (Pubitemid 44942629)
12. Wang L, Yin F, Du YL, et al. MAD2 as a key component of mitotic checkpoint a probable prognostic factor for gastric cancer. Am J Clin Pathol 2009;131:793-801.
13. Yu L, Guo WC, Zhao SH, et al. Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. APMIS 2010;118:222-9.
14. Kato T, Daigo Y, Aragaki M, et al. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer 2011;74:124-31.
15. Rajkumar T, Sabitha K, Vijayalakshmi N, et al. Identification and validation of genes involved in cervical tumourigenesis. Bmc Cancer 2011;11:80.
16. Chang DZ, Ma Y, Ji BA, et al. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 2012;5:15.
17. Kato T, Daigo Y, Aragaki M, et al. Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 2012;106:423-30.
18. Nakano Y, Sumi T, Morishita M, et al. Mitotic arrest deficiency 2 induces carcinogenesis in mucinous ovarian tumors. Oncol Lett 2012;3:281-6.
19. Espinosa AM, Alfaro A, Roman-Basaure E, et al. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One 2013;8:e55975.
20. Li L, Xu DB, Zhao XL, et al. Combination analysis of Bub1 and Mad2 expression in endometrial cancer: Act as a prognostic factor in endometrial cancer. Arch Gynecol Obstet 2013;288:155-65.
21. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2009.
22. Hernando E, Nahle Z, Juan G, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004;430:797-802. (Pubitemid 39071352)
23. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 2002;16:245-56. (Pubitemid 34075816)
24. Sotillo R, Hernando E, Diaz-Rodriguez E, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007;11:9-23. (Pubitemid 46054519)
25. Kabeche L, Compton DA. Checkpoint-independent stabilization of kinetochore-microtubule attachments by Mad2 in human cells. Curr Biol 2012;22:638-44.
26. Patel D, Incassati A, Wang N, et al. Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up-regulation of G2-M-phase proteins. Cancer Res 2004;64:1299-306. (Pubitemid 38235597)